Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure

ClinicalTrials.gov ID: NCT00259038

Public ClinicalTrials.gov record NCT00259038. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Dose Escalation Evaluation of the Pharmacokinetic and Hemodynamic Effects of Carperitide in Subjects With Congestive Heart Failure

Study identification

NCT ID: NCT00259038
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Daiichi Sankyo; Industry
Enrollment: 162 participants

Conditions and interventions

Conditions

Interventions

Carperitide Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2003
Primary completion: Jan 31, 2006
Completion: Jan 31, 2006
Last update posted: Nov 7, 2016

2004 – 2006

United States locations

U.S. sites: 30
U.S. states: 16
U.S. cities: 28

Facility	City	State	ZIP	Site status
Not listed	Huntsville	Alabama	35801	—
Not listed	Los Angeles	California	90033	—
Not listed	Orange	California	92868	—
Not listed	San Diego	California	92103	—
Not listed	Bay Pines	Florida	33744	—
Not listed	Gainesville	Florida	32610	—
Not listed	Jacksonville	Florida	32216	—
Not listed	Miami	Florida	33136	—
Not listed	Orlando	Florida	32803	—
Not listed	St. Petersburg	Florida	33707	—
Not listed	Chicago	Illinois	60611	—
Not listed	Chicago	Illinois	60612	—
Not listed	Springfield	Illinois	62701	—
Not listed	Covington	Louisiana	70433	—
Not listed	Shreveport	Louisiana	71103	—
Not listed	Baltimore	Maryland	21201	—
Not listed	Minneapolis	Minnesota	55455	—
Not listed	St Louis	Missouri	63110	—
Not listed	Albany	New York	—	—
Not listed	Cincinnati	Ohio	45267	—
Not listed	Cleveland	Ohio	44195	—
Not listed	Tulsa	Oklahoma	—	—
Not listed	Charleston	South Carolina	—	—
Not listed	Columbia	South Carolina	—	—
Not listed	Amarillo	Texas	79106	—
Not listed	Houston	Texas	77030	—
Not listed	Houston	Texas	77225	—
Not listed	Richmond	Virginia	23298	—
Not listed	Tacoma	Washington	98405	—
Not listed	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00259038, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 7, 2016 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00259038 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →